Last reviewed · How we verify
Fuadin (stibophen)
Fuadin (generic name: stibophen) is a stibophen drug. It is currently in unknown development for Infection by Schistosoma.
Fuadin works by interfering with the metabolic processes of Schistosoma parasites, ultimately leading to their death.
Fuadin is a trivalent antimony compound used as an anthelmintic, specifically for the treatment of schistosomiasis. It is administered via intramuscular injection.
At a glance
| Generic name | stibophen |
|---|---|
| Drug class | stibophen |
| Therapeutic area | Metabolic |
| Phase | unknown |
Mechanism of action
Imagine Fuadin as a poison that specifically targets the Schistosoma parasite. When taken, it gets inside the parasite's cells and disrupts their ability to make energy, eventually killing them. This allows the body's immune system to fight off the infection more effectively.
Approved indications
- Infection by Schistosoma
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fuadin CI brief — competitive landscape report
- Fuadin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Fuadin
What is Fuadin?
How does Fuadin work?
What is Fuadin used for?
What is the generic name of Fuadin?
What drug class is Fuadin in?
What development phase is Fuadin in?
Related
- Drug class: All stibophen drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Infection by Schistosoma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing